# The Office of HIV/AIDS Network Coordination (HANC)

Russell Campbell, MA
HANC Director

Brian Minalga, MSW HANC Deputy Director

February 18, 2023




## Why we are here today

- Invited
- Listen and learn
- Share
- HIV & other health disparities
- Support Cure agenda



## Dedication





## **HANC** Team














## **HANC Introduction**

Founded in 2004, the mission of the Office of HIV/AIDS Network Coordination is to support the science and operations of the NIAID HIV/AIDS Clinical Trials Networks by increasing efficiency and resource-sharing through coordination of critical activities across networks and with other research and advocacy partners.



### HANC & the NIH-funded HIV Research Networks













#### **CONNECTIONS** GENERAL PUBLIC NIH **EXTERNAL DATA CENTERS COLLABORATORS** HPTN HIV Prevention Trials Network HIV/AIDS Network Coordination **NON-NETWORK HIV ORGS EXTERNAL QA CONTRACTORS** HIV VACCINE **IMPAACT** Clinics






Labs

**Community Representatives** 

**NON-NETWORK COMMUNITY PARTNERS** 





 $a \equiv 1$ 

#### Community



#### Resources for Inclusive Community Involvement

Featured on this page are a list of resources covering various aspects of community engagement in clinical research.

#### On This Page:

Bill of Rights and Responsibilities for HIV Research

Community Engagement Resource Highlights

DAIDS CAB and CWG Directory

**Guidance for Gender-Inclusive HIV Research Practices** 

How to Critically (and Quickly) Read a Protocol

Long-Acting Antiretroviral Injectables Info Sheet

NIAID HIV Language Guide

**PHOENix Study Community Engagement** 

**Recommendations for Community Engagement** 

Representative Studies Rubric

**TB Resources for Communities** 

National Women and Girls HIV/AIDS Awareness

# **Community Resources**

www.hanc.info

## **Cure-Specific Resources: the WHRC**








# The Representative Studies Rubric (RSR)

#### **Addressing Inclusion:**

- Age
- Drug use
- Ethnicity
- Gender
- Pregnancy
- Race
- Sex assigned at birth









#### <del>+</del>

## Recommendations for Community Engagement in HIV/AIDS Research



A guide for communities and researchers

November 2020





Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health

## **Community Resources**

#### How to Critically (and Quickly) Read a Protocol

- Outlines and explains the most important components of a study protocol
- Empowers CABs and community members to advocate
- Available in English,
   Portuguese, and Spanish

## **Community Resources**

## Bill of Rights and Responsibilities for HIV Research

- Outlines the rights and responsibilities for participants in a clinical trial
- Empowers research participants act on their own behalf and in partnership with study staff
- For use by clinical research sites along with informed consent forms

## Mentorship Program

- To support site staff and CABs in an effort to rebuild and reenergize CABs.
- In addition to the Recommendations for Community Engagement document, CP can offer more specific and/or hands-on orientation, consultation, or training.
- Pool of experienced CAB liaisons that sites across the networks can reach out to for mentorship (ex. how to run a CAB meeting, develop your program, schedule trainings, identify critical training needs, prepare bylaws, organize a CAB).
- These individuals who agree to volunteer as mentors would be valuable resource.



## Red Ribbon Registry (R3)

#### www.redribbonregistry.org

A database that connects potential study participants (volunteers) with local clinical studies to strengthen the connection between the community and the doctors and scientists working on clinical research studies.

#### HANC's role:

- Facilitate expansion of the R3 to additional network studies.
- Maintain the R3 Resources page on the HANC website to support ACTG, HPTN, and IMPAACT sites.
- Develop processes and workflows to facilitate various communications between external stakeholders and R3 internal team, including processes for regulatory approval of site-developed advertising materials and requests for communications to volunteers.
- Conduct training sessions for site administrators and users.

## **HANC** Webinar Library

- Behavioral Science (4)
- Community Engagement (6)
- Outreach & Marketing (3)
- Health Disparities (6)
- HIV & Substance Use (3)
- HIV Genetic Sequencing (4)
- Lab (6)

- COVID-19 (9)
- MPV (1)
- TB (5)
- Zika (1)
- National HIV Awareness Days (6)
- Women (4)
- Hot Topics (7)

#### THE LANCET

CORRESPONDENCE | VOLUME 3990, ISSUE 18225, PICEL FERRILARY 12, 2022

Research on transgender people must benefit transgender people
Brian Minalga 2 - Cecilia Chung - J D Davids - A Beks Martin - Nicole Lynn Perry - Alic Shook

#### NATIONAL WOMEN & GIRLS HIV/AIDS AWARENESS DAY

March 10, 2022

The Women's HIV Research Collaborative celebrates these recent advancements in research focused on cis and trans women. Follow us on <u>Facebook</u> for more!

#### A SHOT FOR PREVENTION

No pills? No problem! A bimonthly shot has been approved for HIV prevention in the US and is under review in many other countries. To the more than \$500 transgender women and 3,000 cisgander women who participated in these studies, we have you to thank!





#### HOPE FOR A CURE

Diagnosed with HIV in 2013, a multiracial American woman is showing signs of HIV remission! She in the first woman in the world to do so after receiving a rare treatment for leadward. She and other woman are giving scientists class that may someday lead to a widespread country.

#### A RING FOR PREVENTION

With its first approval in Zimbabwe, a monthly yasinal ring has become the first approved blomedical HIV prevention method designed yeardically for clugender women! <u>Advocacy</u> continues to make it available for all who need it.



#### TRANSGENDER WOMEN

Two major research retworks are launching their very first studies designed exclusively for transfermine people! Learn more about the 1 km study, and stay tuned for the "Get it Right" study. Both studies are looking at gender-affirming hormones and HIV.

#### HIV VACCINE RESEARCH

Thousands of women have participated in studies trying to discover an HIV vaccine. The search continues in the Mosaico study, which is fully enrolled with about 3,800 people, including transgender women.



#### PREGNANCY & BREASTFEEDING

Pregnant and breatfeeding people are too often excluded from research, leaving them and their doctors unsure what to do when drugs are needed for treatment and prevention. Thankfully, new guidance has been issued to accelerate the inclusion of pregnant and breastleeding people in HIV research.





# REPRESENTATION MATTERS

By Pedro Goicochea, MSC, MA and Tasia Baldwin, MSC, MA on behalf of the Latinx Caucus\*



SocArXiv Papers

Lessons Learned from Community Engagement Regarding Phylodynamic Research with Molecular HIV Surveillance Data

AUTHORS

Diana M. Tordoff, Brian Minalga, Alfredo Trejo, Alic Shook, Roxanne P. Kerani, Joshua T. Herbeck

## JOURNAL of COMMUNITY ENGAGEMENT and SCHOLARSHIP

The Meaningful Involvement of People with HIV/AIDS (MIPA): The Participatory Praxis Approach to Community Engagement on HIV Surveillance

Authors: Andrew Spieldenner, Martin French, Venita Ray,
Brian Minalga, Cristine Sardina, Robert Suttle,
Marco Castro-Bojorquez, Octavia Lewis, Laurel Sprague



TO END THE AIDS EPIDEMIC

## Thank you!







Conversation



Russell Campbell rcampbel@fredhutch.org

Brian Minalga bminalga@fredhutch.org

## **Background**

- As a whole HIV clinical research is not representative of the HIV epidemic.
- Cisgender White men make up 6% of the global epidemic but 51% of participants in RCTs for new ARVs.\*
- Underrepresented populations suffer the consequences of exclusion:
  - -Cisgender women, transgender people, pregnant people, and PWID globally
  - -Black, Indigenous, and Latinx people in the US and territories

<sup>\*</sup>Pepperrell, T., Hill, A., Moorhouse, M., Clayden, P., McCann, K., Sokhela, S., Serenata, C., & Venter, W. (2020). Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. Journal of virus eradication, 6(2), 70-73.

### The RSR: 12-Item Questionnaire


#### 1-7: Eligibility

- 1. Age
- 2. Cisgender women
- 3. Gender non-binary individuals
- 4. Persons who inject drugs
- 5. Transgender men
- 6. Transgender women
- 7. Pregnancy


- 8-12: Processes to Support Representation
- 8. Enrollment Goals (incl. ethnicity & race)
- 9. Community Engagement
- 10. Statistical Analysis: Gender & Sex
- 11. Defining Gender & Sex
- 12. Language (stigma)


## **Protocol Analysis (47)**

- AIDS Clinical Trials Group (21)
- International, Maternal, Pediatric, Adolescent AIDS Clinical Trials Network (10)
- HIV Prevention Trials Network (5)
- HIV Vaccine Trials Network (5)
- HPTN/HVTN (3)
- Microbicide Trials Network (2)
- COVID-19 Prevention Network (1)



#### Specific and Measurable Enrollment Goals





## NIAID HIV Language Guide

• All 47 protocols included at least one instance of stigmatizing language

HIV-infected / HIV-uninfected

Infection / infect

Risk / low-risk / high-risk / at-risk (referring to participants)

Subjects (referring to participants)

Target (referring to participants)

## **Conclusions & Next Steps**

- Institutionalized barriers are ongoing and may perpetuate the underrepresentation of certain populations
- Proactive implementation of the RSR for all future protocols
- RSR Working Group
- RSR pilots
- Revise protocol templates
- Publish findings and promote the RSR for use in all clinical trials